logo
  • ABOUT US
    • Our Story
    • Message From Our CEO
    • Leadership Team
    • Board Members
    • Guiding Principles
    • Join Us
  • OUR SCIENCE
    • Our Approach
    • Our Focus
      • MZL/FL
      • CLL
      • MS
    • Collaborate With Us
  • OUR PRODUCTS
  • OUR PIPELINE
    • Overview
    • Umbralisib
    • Ublituximab
    • TG-1501
    • TG-1701
    • TG 1801
  • OUR PUBLICATIONS
  • OUR TRIALS
    • Trial Information
    • Expanded Access Policy
  • INVESTORS & MEDIA
    • Press Releases
    • Stock Information
      • Historic Stock Lookup
    • Sec Filings & Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Events
    • IR & Media Contact
    • Leadership Team
    • Corporate Governance
    • Faqs
logo
Mobile Menu Mobile Close
  • ABOUT US
    • Our Story
    • Message From Our CEO
    • Leadership Team
    • Board Members
    • Guiding Principles
    • Join Us
  • OUR SCIENCE
    • Our Approach
    • Our Focus
      • MZL/FL
      • CLL
      • MS
    • Collaborate With Us
  • OUR PRODUCTS
  • OUR PIPELINE
    • Overview
    • Umbralisib
    • Ublituximab
    • TG-1501
    • TG-1701
    • TG 1801
  • OUR PUBLICATIONS
  • OUR TRIALS
    • Trial Information
    • Expanded Access Policy
  • INVESTORS & MEDIA
    • Press Releases
    • Stock Information
      • Historic Stock Lookup
    • Sec Filings & Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Events
    • IR & Media Contact
    • Leadership Team
    • Corporate Governance
    • Faqs
  • Search

    LEARN MORE AT UKONIQ.COM LEARN MORE AT UKONIQ.COM

    LEARN MORE ABOUT OUR FEARLESS PURSUIT

    LATEST NEWS

    TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Me...

    NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been

    Read More >

    GET INVESTOR
    INFORMATION

    HEAR OUR
    STORY

    READ OUR
    PUBLICATIONS

    EXPLORE OUR
    PIPELINE

    JOIN OUR
    TEAM

    HEAR OUR
    STORY

    EXPLORE OUR
    PIPELINE

    READ OUR
    PUBLICATIONS

    JOIN OUR
    TEAM

    GET INVESTOR
    INFORMATION

    LATEST NEWS

    TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Me...

    NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been

    Read More >

    GET INVESTOR
    INFORMATION

    HEAR OUR
    STORY

    READ OUR
    PUBLICATIONS

    EXPLORE OUR
    PIPELINE

    JOIN OUR
    TEAM

    logo

    Email Us 1-877-575-TGTX (8489)

    ©2021 TG Therapeutics, Inc. All rights reserved.

    • Join Us
    • CONTACT US
    • Expanded Access Policy
    • PRIVACY POLICY
    • Terms of Use

    You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

    CONTINUE Return to tgtherapeutics.com